Therapeutic Asset Ratings

6,308 results matching 1 filter

91,564 assets · 7,904 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Primepro™/ Primemsk™ Integumentary System Disorder	Thomas Advanced Medical LLC	P1/2	CCC (48)
Primepro™/ Primemsk™ Musculoskeletal System Disorder	Thomas Advanced Medical LLC	P1/2	CCC (48)
Primepro™/ Primemsk™ Lung Disorder	Thomas Advanced Medical LLC	P1/2	CCC (48)
Primepro™/ Primemsk™ Sexual Disorder	Thomas Advanced Medical LLC	P1/2	CCC (48)
Primepro™/ Primemsk™ Urinary System Disorder	Thomas Advanced Medical LLC	P1/2	CCC (48)
Primepro™/ Primemsk™ Viral Infectious Disease	Thomas Advanced Medical LLC	P1/2	CCC (48)
Psilocin Depressive Disorder	Federal University of Latin American Integration	P1/2	CCC (48)
Pumitamig Renal Cell Carcinoma	Bristol-Myers Squibb	P1/2	CCC (48)
Pumitamig Gastroesophageal Junction Adenocarcinoma	Bristol-Myers Squibb	P1/2	CCC (48)
Purinostat Plasma Cell Myeloma	Chengdu Zenitar Biomedical Technology Co., Ltd	P1/2	CCC (48)
Puxitatug Samrotecan Biliary Tract Cancer	AstraZeneca	P1/2	CCC (48)
Puxitatug Samrotecan Squamous Cell Lung Carcinoma	AstraZeneca	P1/2	CCC (48)
Quemliclustat Urinary Bladder Cancer	Fred Hutchinson Cancer Center	P1/2	CCC (48)
Quizartinib Myelodysplastic Syndrome With Excess Blasts	M.D. Anderson Cancer Center	P1/2	CCC (48)
Quizartinib Acute Biphenotypic Leukemia	M.D. Anderson Cancer Center	P1/2	CCC (48)
Radiprodil Tuberous Sclerosis	GRIN Therapeutics, Inc.	P1/2	CCC (48)
Raltitrexed Refractory Malignant Neoplasm	China Medical University, China	P1/2	CCC (48)
Rec-1245 Metastatic Malignant Neoplasm	Recursion Pharmaceuticals Inc.	P1/2	CCC (48)
Recombinant Human Egf-Rp64K Head And Neck Squamous Cell Carcinoma	Roswell Park Cancer Institute	P1/2	CCC (48)
Recombinant Human Egf-Rp64K Skin Squamous Cell Carcinoma	Roswell Park Cancer Institute	P1/2	CCC (48)
Recombinant Human Granulocyte Colony-Stimulating Factor Myeloid Sarcoma	University of Washington	P1/2	CCC (48)
Regn10597 Clear Cell Renal Carcinoma	Regeneron Pharmaceuticals	P1/2	CCC (48)
Regn17372 Plasma Cell Myeloma	Regeneron Pharmaceuticals	P1/2	CCC (48)
Regorafenib Ewing Sarcoma Of Bone	Institute of Mother and Child, Warsaw, Poland	P1/2	CCC (48)
Relatlimab Triple-Negative Breast Carcinoma	Yale University	P1/2	CCC (48)

Showing 1701 to 1725 of 6,308 assets

PreviousPage 69 of 253Next